Building a Clinical Advisory Board for Healthtech Startups

Most healthtech founders build a clinical advisory board for the pitch deck

If you are searching for how to build a clinical advisory board for a healthtech startup, you are probably trying to do two things at once: get a credible name on your deck before the next round, and find someone who actually understands the NHS workflow your product needs to slot into. Those are different jobs, they need different people, and you should not try to solve them with the same board seat. The startups that survive their first MHRA review and their first NHS procurement bid are the ones that worked this out before they made offers.

Why most healthtech advisory boards fail at first regulator contact

A pitch-deck advisory board is recruited backwards. You pick three consultants from a top London teaching hospital, give them 0.25% each, and put them on your website. You never speak to them again, except to ask for a CCIO introduction before a round closes.

When you submit DTAC v2 or a clinical evaluation report, you discover that none of them have actually used your product in a clinical setting, none of them sit close enough to your indication to defend your evidence base, and none of them carry the registration profile that the regulator actually wants to see on your risk file.

That is the failure pattern. Babylon Health was the most public version of it. UK regulators and frontline NHS clinicians raised safety concerns about its symptom checker for years before the company entered administration in September 2023 and sold its assets for £500,000 to EMED Healthcare.

Senior names on the board did not catch what a working clinical safety officer would have caught at the design stage. A clinical advisory board is a clinical risk control, not a marketing asset. Treat it as marketing and your regulator will treat it as an empty seat.

The four functional seats you actually need

Forget the generic "advisor" title. A working clinical advisory board for a UK healthtech has four functional seats, and the people filling them are usually not all consultant doctors.

The clinical credibility lead. A senior clinician registered with the relevant regulator (GMC, NMC, HCPC, GPhC) who works currently in your therapy area, signs off your clinical evaluation, sits in your clinical risk meetings, and validates your intended use statement. In mental health, allied health, or pharmacy-led indications, this is a senior nurse, psychologist, AHP, or pharmacist, not a hospital consultant.

The frontline workflow expert. A staff nurse, paramedic, CT radiographer, or band 7 physiotherapist who actually uses tools like yours in a live NHS setting. They tell you what breaks when your product hits a real ward at 3am with one logged-in user and an EPR that has just timed out. Most founders skip this seat and pay for it in pilot abandonment.

The regulatory and safety lead. A clinical safety officer who can write a DCB0129 hazard log and defend it, ideally one who has signed off a product through DTAC v2 since the April 2026 refresh. On the buy-side, do not confuse a CSO with a generic regulatory consultant. They do different jobs and produce different artefacts.

The system access advisor. An NHS digital lead, a former ICB digital director, a head of transformation, or a health economist who has built a payer evidence model. They tell you which framework to target, what NICE will demand under the Evidence Standards Framework, and where your business case will get torn apart.

Some startups try to collapse all four roles into two people. That works if the people are exceptional. Most are not, and most boards built that way quietly drop the role with the lowest internal status, which is usually the frontline workflow seat.

What to pay them in the UK in 2026

Equity at the seed and pre-seed stage runs 0.25% to 1% per advisor on a two-year vest with a three-month cliff. The Series A range narrows to 0.1% to 0.5%. Reserve the top of the range for the credibility lead and the CSO, and the lower end for the workflow and access seats unless one of those people is exceptional.

Cash day rates for substantive UK clinical advisory work in 2026 sit between £900 and £1,500 for consultants and CSOs, and £400 to £700 for senior nurses, AHPs, and clinical scientists. Pure pitch-deck advisors should be on equity only, because anyone taking a serious advisory role expects to be paid for the work, not the name. Pay them by invoice through their consulting limited company, never through NHS payroll, and require them to handle their own HMRC IR35 status and trust declaration.

If a clinical advisor is willing to take 1% equity and never invoice you for time, they are not planning to do any work.

How to actually run the board

A board you do not run is worse than no board, because it produces a documented trail of inattention. The minimum cadence is a quarterly two-hour structured meeting, with written pre-reads sent five working days in advance and minuted decisions afterwards. Between meetings, individual advisors are on call for specific decisions in their lane, billed against a retainer or per-meeting rate.

Keep three things in writing: a signed advisor agreement covering IP, confidentiality, conflicts of interest, and equity terms; a current declaration of interests log, refreshed annually, with their substantive employer, other commercial roles, and any patient-facing work in your indication; and a clinical risk participation record naming which advisor signed which version of your hazard log, your intended use statement, and your evidence summary.

The NHS and the MHRA will both ask for these. Not having them is a closeable finding that costs you weeks of remediation at the worst possible point in your sales cycle.

Three patterns: a startup that did it right, the NHS doing it inside, and one that did it wrong

A Series A digital therapeutics company in adolescent mental health that we have seen do this well had four named advisors by the time it filed for DTAC v2. A consultant psychiatrist as credibility lead, a senior CAMHS nurse for workflow, an external CSO on retainer, and a former NHS digital director as the access seat. The board met quarterly, signed off two hazard log revisions in 2025, and the company passed DTAC at first submission with around 2.5% of the cap table allocated across the four.

The NHS uses the same structure internally, but you rarely see it from the outside. Every national NHS England digital service has a Clinical Reference Group of practising clinicians who sign off the clinical safety case on its platforms, and the CRG validated the safety case when the NHS App took major upgrades through 2024 and 2025. If the NHS itself uses a structured clinical advisory body to ship its own products, your startup should not skip the equivalent governance.

The failure pattern is Babylon Health: famous advisors, weak internal clinical safety capability, and an avoidant response when frontline clinicians raised concerns. The Sifted post-mortem documents that the company was warned repeatedly from inside and outside, including by NHS oncologist Dr David Watkins, and that those warnings did not change the product. A working advisory board would have stopped that product going to market in that form; the cost of not having one ran to a $4.2bn valuation collapse and a £500,000 fire sale.

What to do this week

You should be able to write down which of the four seats you currently have filled, and which are empty. If you have three or four people who all do the same job, you do not have a board, you have a panel.

You should be able to email each current advisor and ask them three questions: when did we last meet, have you signed any version of our hazard log, and can you list your other current commercial roles. If you do not get a useful answer in 48 hours from any of them, that seat is empty even if the photo is still on your website.

You should be able to budget for the missing seats. Two retained advisors at £4,000 to £6,000 per quarter each, plus a CSO on a project retainer of £15,000 to £25,000 per year, plus 1.5% to 2.5% equity reserved in the option pool. That is the working number for a Series A UK healthtech in 2026.

Orbion Connect exists because most UK healthtech startups cannot find these four people inside their own network. See case studies of how teams have filled specific advisory seats through the marketplace, and read about how we vet experts on the sell-side. If you are recruiting your board this quarter, start with the seat you are most afraid to fill, because that is almost always the one your regulator and your future NHS buyer will care about first.